Monday, June 01, 2020 3:18:59 PM
April 14, 2020
Fourth largest Medicaid population in the U.S.
For a pdf of this press release click here
AUSTIN, Texas, April 14, 2020 –Vermillion, Inc. (NASDAQ: VRML) today announced its wholly owned subsidiary, ASPiRA LABS, is now credentialed with Florida’s State Medicaid program for an estimated additional 3.6 million credentialed Medicaid lives.
Florida has the fourth largest state Medicaid populations in the U.S. and ASPiRA is now credentialed in 4 of the top 5 states by Medicaid population size, including California, Pennsylvania, Texas and now Florida. The state of New York has the second largest state Medicaid population and ASPIRA LABS is in process of seeking credentials there. Florida brings the total credentialed Medicaid population to almost 50 M Medicaid lives, which is about 77% of the U.S. Medicaid population. This credentialing also allows ASPiRA LABS to seek participation as a network provider with commercial Medicaid health plans. ASPiRA LABS is the only U.S. provider for Vermillion’s proprietary OVA1® test, an FDA-cleared, ACOG recommended and CMS supported ovarian cancer risk assessment for women with a pelvic mass.
Credentialing is an important step towards gaining additional positive coverage for OVA1®, and follow-on commercial Medicaid contracts, especially when combined with peer-reviewed published evidence documenting OVA1®’s early detection and negative predictive value performance over CA125, and its marked performance in African American women as compared to CA125.
“Actively pursuing Medicaid providership is a key cornerstone to our Disparity Gap movement. We are pleased to announce ASPiRA’s enrollment as a participating provider with Medicaid in the state of Florida,” said Valerie Palmieri, President and CEO of Vermillion, Inc. As stated on our most recent earnings call, it is now time that ALL women of every socioeconomic background receive the best care possible and we are proud and excited to play our part in making that happen.”
Recent AWH News
- Aspira Women’s Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:00 AM
- Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference • GlobeNewswire Inc. • 03/21/2024 12:00:00 PM
- Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024 • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference • GlobeNewswire Inc. • 02/22/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 01:54:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:17:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:11:43 AM
- Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/07/2024 09:21:10 PM
- Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 01:31:35 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/26/2024 10:25:56 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/26/2024 10:19:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/26/2024 10:12:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:39:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:41:58 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/26/2023 10:17:07 PM
- Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024 • GlobeNewswire Inc. • 12/19/2023 01:00:00 PM
- Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024 • GlobeNewswire Inc. • 12/14/2023 01:00:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM